Iterum Therapeutics PLC (ITRM NASDAQ) stock market data APIs
$0.6807
-0(-0%)
as of September 16, 2025
Try our APIs with
free plan!
Iterum Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Prev. Close
0.6807
Open
0.6764
High
0.693
Low
0.6647
52 wk Range
0.6108-3.02
Market Cap
30 335 K
Shares Outstanding
44 657 K
EPS
-0.16
Beta
3.039
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Iterum Therapeutics PLC data using free add-ons & libraries
Get Iterum Therapeutics PLC Fundamental Data
Iterum Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -16 827 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Iterum Therapeutics PLC News
New
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by mu...
Iterum Therapeutics PLC (NASDAQ:ITRM) Reports Wider Q2 2025 Loss, Market Optimistic Ahead of ORLYNVAH Launch
ITERUM THERAPEUTICS PLC (NASDAQ:ITRM [https://www.chartmill.com/stock/quote/ITRM/profile] REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, MARKET REACTS POSITIVELY AHEAD OF KEY LAUNCH Iterum Thera...
Iterum Therapeutics Non-GAAP EPS of -$0.13
* Iterum Therapeutics press release [https://seekingalpha.com/pr/20188670-iterum-therapeutics-reports-second-quarter-2025-financial-results] (NASDAQ:ITRM [https://seekingalpha.com/symbol/ITRM]): Q2 ...
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
-- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therap...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
